These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 27665287)

  • 41. Palivizumab prophylaxis to prevent respiratory syncytial virus mortality after pediatric bone marrow transplantation: a decision analysis model.
    Thomas NJ; Hollenbeak CS; Ceneviva GD; Geskey JM; Young MJ
    J Pediatr Hematol Oncol; 2007 Apr; 29(4):227-32. PubMed ID: 17414564
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Nationwide survey of severe respiratory syncytial virus infection in children who do not meet indications for palivizumab in Japan.
    Mori M; Kawashima H; Nakamura H; Nakagawa M; Kusuda S; Saji T; Tsutsumi H; Yokota S; Itoh S;
    J Infect Chemother; 2011 Apr; 17(2):254-63. PubMed ID: 20872156
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Efficacy of palivizumab prophylaxis on the frequency of RSV-associated lower respiratory tract infections in preterm infants: determination of the ideal target population for prophylaxis.
    Cetinkaya M; Oral TK; Karatekin S; Cebeci B; Babayigit A; Yesil Y
    Eur J Clin Microbiol Infect Dis; 2017 Sep; 36(9):1629-1634. PubMed ID: 28391538
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group.
    Pediatrics; 1998 Sep; 102(3 Pt 1):531-7. PubMed ID: 9738173
    [TBL] [Abstract][Full Text] [Related]  

  • 45. CHD and respiratory syncytial virus: global expert exchange recommendations.
    Tulloh RMR; Medrano-Lopez C; Checchia PA; Stapper C; Sumitomo N; Gorenflo M; Jung Bae E; Juanico A; Gil-Jaurena JM; Wu MH; Farha T; Dodge-Khatami A; Tsang R; Notario G; Wegzyn C
    Cardiol Young; 2017 Oct; 27(8):1504-1521. PubMed ID: 28619123
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Palivizumab prophylaxis, respiratory syncytial virus, and subsequent recurrent wheezing.
    Simoes EA; Groothuis JR; Carbonell-Estrany X; Rieger CH; Mitchell I; Fredrick LM; Kimpen JL;
    J Pediatr; 2007 Jul; 151(1):34-42, 42.e1. PubMed ID: 17586188
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Incidence of respiratory syncytial virus-related hospitalizations in high-risk children: follow-up of a national cohort of infants treated with Palivizumab as RSV prophylaxis.
    Lacaze-Masmonteil T; Rozé JC; Fauroux B;
    Pediatr Pulmonol; 2002 Sep; 34(3):181-8. PubMed ID: 12203846
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Respiratory syncytial virus prophylaxis in cystic fibrosis: the Canadian registry of palivizumab data (2005-2016).
    Mitchell I; Wong SK; Paes B; Ruff M; Bjornson C; Li A; Lanctôt KL;
    Eur J Clin Microbiol Infect Dis; 2018 Jul; 37(7):1345-1352. PubMed ID: 29728782
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Efficacy and long-term outcomes of palivizumab prophylaxis to prevent respiratory syncytial virus infection in infants with cystic fibrosis in Northern Ireland.
    Groves HE; Jenkins L; Macfarlane M; Reid A; Lynn F; Shields MD
    Pediatr Pulmonol; 2016 Apr; 51(4):379-85. PubMed ID: 26808981
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Respiratory syncytial virus prophylaxis in children with cardiac disease: a retrospective single-centre study.
    Butt M; Symington A; Janes M; Steele S; Elliott L; Chant-Gambacort C; Mondal T; Paes B
    Cardiol Young; 2014 Apr; 24(2):337-43. PubMed ID: 23628233
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Use of palivizumab with other infection control measures to control respiratory syncytial virus outbreaks in neonatal care units.
    Hammoud MS; Al-Taiar A; Raina A; Elsori D; Al-Qabandi S; Al-Essa M
    J Trop Pediatr; 2016 Oct; 62(5):409-14. PubMed ID: 27118823
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Palivizumab for respiratory syncytial virus prophylaxis.
    Sandritter T
    J Pediatr Health Care; 1999; 13(4):191-5; quiz 196-7. PubMed ID: 10690084
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Outcomes of Respiratory Syncytial Virus Immunoprophylaxis in Infants Using an Abbreviated Dosing Regimen of Palivizumab.
    Lavoie PM; Solimano A; Taylor R; Kwan E; Claydon J; Turvey SE; Marr N
    JAMA Pediatr; 2016 Feb; 170(2):174-6. PubMed ID: 26720836
    [No Abstract]   [Full Text] [Related]  

  • 54. Prophylaxis against respiratory syncytial virus in young children with cystic fibrosis.
    Giebels K; Marcotte JE; Podoba J; Rousseau C; Denis MH; Fauvel V; Laberge S
    Pediatr Pulmonol; 2008 Feb; 43(2):169-74. PubMed ID: 18085710
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Palivizumab prophylaxis in infants with cystic fibrosis does not delay first isolation of Pseudomonas aeruginosa or Staphylococcus aureus.
    Buchs C; Dalphin ML; Sanchez S; Perceval M; Coutier L; Mainguy C; Kassaï-Koupaï B; Reix P
    Eur J Pediatr; 2017 Jul; 176(7):891-897. PubMed ID: 28508992
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Nosocomial respiratory syncytial virus infections in the palivizumab-prophylaxis era with implications regarding high-risk infants.
    Ashkenazi-Hoffnung L; Dotan M; Livni G; Amir J; Bilavsky E
    Am J Infect Control; 2014 Sep; 42(9):991-5. PubMed ID: 25179332
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Restrictive Palivizumab Use Does Not Lead to Increased Morbidity and Mortality in Pediatric Hematopoietic Stem Cell Transplantation Patients.
    Teusink-Cross A; Davies SM; Danziger-Isakov L; El-Bietar J; Grimley MS
    Biol Blood Marrow Transplant; 2016 Oct; 22(10):1904-1906. PubMed ID: 27422147
    [TBL] [Abstract][Full Text] [Related]  

  • 58. RSV Hospitalizations in Comparison With Regional RSV Activity and Inpatient Palivizumab Administration, 2010-2013.
    Glick AF; Kjelleren S; Hofstetter AM; Subramony A
    Hosp Pediatr; 2017 May; 7(5):271-278. PubMed ID: 28381595
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Direct cost analyses of palivizumab treatment in a cohort of at-risk children: evidence from the North Carolina Medicaid Program.
    Wegner S; Vann JJ; Liu G; Byrns P; Cypra C; Campbell W; Stiles A
    Pediatrics; 2004 Dec; 114(6):1612-9. PubMed ID: 15574623
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Palivizumab: new indication. Moderate reduction in hospitalisation rate.
    Prescrire Int; 2004 Dec; 13(74):213-6. PubMed ID: 15612142
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.